Prestige Biologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Prestige Biologics provides contract manufacturing and development services for advanced biologic medicines, complex drugs derived from living cells, on behalf of pharmaceutical companies in Korea and abroad.
It sits in the supply chain as a service provider, handling production and development-stage support rather than marketing its own drugs. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates under a model it calls CDEMO (Contract Development, Engineering and Manufacturing Organization), offering clients a flexible manufacturing environment that can be adapted to their specific needs.
Summary is AI-generated and may contain errors · figures from DART filings
Prestige Biologics in five facts
What does Prestige Biologics do?
Prestige Biologics provides contract manufacturing and development services for advanced biologic medicines, complex drugs derived from living cells, on behalf of pharmaceutical companies in Korea and abroad.
Where is Prestige Biologics listed and in which sector?
Prestige Biologics (Korean name: 프레스티지바이오로직스) trades under KRX code 334970 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Prestige Biologics?
Its market capitalisation was US$76.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Prestige Biologics's latest annual revenue and operating profit?
For fiscal year 2025, Prestige Biologics reported revenue of US$9.5M, an operating loss of US$25.4M and a net loss of US$20.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 477.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureSep 30
- Other material management matterSep 30
- Results of annual shareholders' meetingSep 30
- [Amended] Annual report (2026.06)Sep 28
- [Amended] Supply contract signedSupply contract · Sep 21 · 2 versions
- Auditor's report filedSep 18
- Annual report (2026.06)Sep 18
- Resolution to convene a general shareholders' meetingSep 11
- DisclosureSep 11
- Notice of general shareholders' meetingSep 11
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Prestige Biologics reported separate results for the fiscal year ended Jun 2026: revenue of US$16.8M (+90% year on year), an operating loss of US$34.7M and a net loss of US$36.4M.
Earnings · Aug 14 - [Amended] Supply contract signed
Prestige Biologics updated a previously disclosed supply contract with Celltrion, now worth US$1.36M, about 15.4% of its recent annual revenue, running through Jul 2026.
Supply contract · Jul 31 - [Amended] Material event report (convertible bonds)
Prestige Biologics updated the terms of convertible bonds to raise US$29.6M, about 41.2% of its market value.
Capital raise · Jun 22 - Supply contract signedSupply contract · Jun 10
- Supply contract terminatedSupply contract · Apr 30
- [Amended] Supply contract signedSupply contract · Apr 30